FDA says 561 deaths tied to recalled Philips sleep apnea machines

Original Article ↗ Hacker News Discussion ↗

Philips’ recall of millions of CPAP and BiPAP sleep apnea machines over degrading sound-dampening foam has been linked by the FDA to more than 500 reported deaths and tens of thousands of injury reports, including cancer and serious respiratory problems. Commenters describe foam particles and toxic gases being blown into users’ airways, slow or inadequate recall and replacement efforts, and a settlement that so far mostly covers device costs rather than health impacts. The incident fuels wider criticism of Philips’ management and the FDA’s post‑market oversight, while patients weigh the risks of the devices against the dangers of untreated sleep apnea and explore alternatives like ResMed machines, oral appliances, surgery, and lifestyle changes.

Mechanism of Harm and Reported Injuries

  • Core issue: sound-dampening polyester polyurethane foam in Philips CPAP/BiPAP/ventilators degrades, sending particles and volatile organic compounds (VOCs) into the airflow.
  • Reported or suspected effects: respiratory irritation, asthma, pneumonia, possible cancer, organ toxicity, headaches, cough, and possibly lung fibrosis / pulmonary fibrosis (IPF) and other long‑term lung damage.
  • Some users report visible black residue on masks, strong plastic/chemical odors, and “blackened” filters. Others saw no obvious signs.

Recall Handling, Settlement, and Scope

  • Many users describe recall logistics as slow, opaque, and outsourced to third‑party sites that felt “shady.”
  • Replacement/repair settlement (~$400M) is said to cover financial/device damage only, not personal injury or medical monitoring, leaving room for future lawsuits.
  • Non‑US users complain about weaker recall coverage and compensation routes, needing to pursue local legal options.

User Tradeoffs: CPAP Risks vs. Untreated Apnea

  • Several note untreated apnea is itself dangerous and life‑ruining; some continue using recalled devices due to lack of alternatives.
  • Others switched to ResMed devices, oral appliances, or loaner machines and report major quality‑of‑life gains with effective, safer therapy.
  • Experiences with CPAP comfort and noise vary widely; mask choice, machine placement, and settings matter.

Alternatives and Mitigation Strategies

  • Reported alternatives:
    • Custom oral appliances / mandibular advancement devices (mixed reports: life‑changing for some, jaw/teeth pain and misalignment for others).
    • Weight loss, exercise, smoking reduction; sometimes highly effective, sometimes not (especially anatomy‑driven apnea).
    • Surgical options (septoplasty, turbinate reduction, UPPP, jaw surgery) with both strong success stories and serious risk/horror anecdotes.
    • Tongue/jaw exercises, positional therapy, nasal strips/cones, mouth taping (controversial safety), experimental TENS approaches.

Corporate and Regulatory Critique

  • Strong condemnation of Philips for allegedly sitting on internal complaints and not promptly notifying FDA or patients.
  • Some argue for criminal liability for executives and even “corporate death penalty”; others stress need to distinguish anger from legal standards.
  • FDA criticized for ineffective post‑market surveillance, slow response, and focusing on other areas (like lab‑developed tests) while missing hundreds of deaths here.

Broader Reflections

  • Discussion connects this case to broader patterns: medical‑device QMS failures, “too big to punish” corporations, and comparisons with aviation scandals.
  • Some raise concerns about microplastics and inhaled particulates generally, while others stress this case is specific to this foam and device context.